Stockreport

Actinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for ATNM-400 in Solid Tumors and Differentiated Mechanism for Actimab-A in AML to be Presented at 2026 AACR Annual Meeting...

Actinium Pharmaceuticals, Inc. (Delaware)  (ATNM) 
NASDAQ:AMEX Investor Relations: ir.actiniumpharma.com
PDF Actimab-A demonstrates mutation-agnostic efficacy and a novel mechanism that enhances response to standard AML therapies Multiple data catalysts for ATNM-400 and Acti [Read more]